NDTV-Dettol Banega Swasth Swachh India NDTV-Dettol Banega Swasth Swachh India
  • Home/
  • News/
  • India’s COVID Vaccine Supply Jumps, Raising Export Hopes

News

India’s COVID Vaccine Supply Jumps, Raising Export Hopes

According to a spokesperson for the COVAX co-lead GAVI, India, a major international producer of many other vaccines, could play a similarly transformative role in the global response to COVID-19

India's COVID Vaccine Supply Jumps, Raising Export Hopes
Highlights
  • India donated or sold 66 million doses to nearly 100 countries
  • India's daily vaccinations surpassed 10 million doses on Friday
  • India could produce around 1.1 billion doses between Sept-Oct: Centre

New Delhi: India’s rising output of COVID-19 vaccines and the inoculation of more than half its adult population with at least one dose are raising hopes the country will return as an exporter within months, ramping up from early next year. After donating or selling 66 million doses to nearly 100 countries, India barred exports in the middle of April to focus on domestic immunisation as infections exploded, upsetting the inoculation plans of many African and South Asian countries.

Also Read: COVID-19 Bigger Blood Clot Threat Than Vaccines, UK Study Finds

India’s daily vaccinations surpassed 10 million doses on Friday, with national vaccine production more than doubling since April and set to rise again in the coming weeks, and commercial production of Russia’s Sputnik V is starting in India.

The Serum Institute of India (SII), the world’s biggest vaccine maker, is now producing about 150 million doses a month of its version of the AstraZeneca shot, more than twice its April output of about 65 million, a source with knowledge of the matter said.

No fixed timeline on exports but the company hopes to restart in a few months, said the source, who declined to be named without approval to talk on the matter.

SII, which has previously indicated exports could resume by year-end did not respond to a request for comment.

Global vaccine sharing platform COVAX hopes India will restart foreign sales sooner than later.

With successful national vaccination and the arrival of more products, we are hoping that Indian supply to COVAX will resume as quickly as possible, a spokesperson for the platform’s co-lead GAVI told Reuters in an email.

India, a major international producer of many other vaccines, could play a “similarly transformative role in the global response to COVID-19,” the spokesperson said.

Also Read: Please Send Your Child To School, Families And School Staff Should Be Vaccinated: Dr NK Arora, Expert Panel Chief

India’s health ministry and the foreign ministry, which coordinates vaccine exports, did not respond to a request for comment.

Bharat Biotech, the maker of India’s first domestically developed COVID-19 shot, on Sunday inaugurated a new factory with a production capacity of 10 million doses a month. It said it was “marching towards” a goal of a total annual capacity of about 1 billion doses of the drug, Covaxin.

Infections, meanwhile, are again rising in India after an explosive outbreak in April and May. But the country has administered more than 633 million vaccine doses, with at least one dose to 52% of its 944 million adults and two doses to more than 15%.

A government source told Reuters in June the U.S. experience showed that vaccinations tend to slow down after a big majority of people get their shots. That might give SII a chance to export excess output, said the source.

The chief of Prime Minister Narendra Modi’s party said this month India could produce as many as 1.1 billion vaccine doses between September and December, enough to fully immunise all adults in the country this year.

India has so far given emergency authorisation to six COVID-19 shots, four of which are being produced locally. One more domestic vaccine is expected to be approved soon while many more are going through mid-stage trials.

Also Read: Protection From Pfizer And AstraZeneca’s COVID-19 Vaccine Wanes Within Six Months: UK Study

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

[corona_data_new]
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This website follows the DNPA Code of Ethics

© Copyright NDTV Convergence Limited 2024. All rights reserved.